

ANTIHEMOPHILIA AGENTS PRIOR AUTHORIZATION FORM

(form effective 1/8/2024)

Fax to PerformRxSM at **1-855-851-4058**, or to speak to a representative call **1-866-907-7088**.



Keystone First
Community HealthChoices

PERFORMRxSM

Next Generation Pharmacy Benefits

PRIOR AUTHORIZATION REQUEST INFORMATION

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # pages:
Name of office contact:		Contact's phone number:

PATIENT INFORMATION

Patient name:	Patient ID #:	DOB:
Street address:		
Apt #:	City/state/zip:	Phone:

PRESCRIBER INFORMATION

Prescriber name:	Specialty:	NPI:
Street address:		
Suite #:	City/state/zip:	
Phone:	Fax:	

CLINICAL INFORMATION

Product requested: <input type="checkbox"/> Hemlibra	<input type="checkbox"/> Factor (name):	J-code:	Weight:	lbs/kg
Strength/vial size:		# of vials:	NDC#:	
Strength/vial size:		# of vials:	NDC#:	
Administration date: (to) (from)		Dispense date:		
DX code (required):		Diagnosis (submit documentation):		
Directions:		Total quantity requested:	Duration:	

PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):

Deliver to: <input type="checkbox"/> Patient's Home	<input type="checkbox"/> Physician's Office	<input type="checkbox"/> Patient's Preferred Pharmacy Name:
NPI#:		
Pharmacy Phone #:	Pharmacy Fax #:	
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.		

INITIAL REQUESTS (Complete the section(s) below applicable to the patient and this request and SUBMIT DOCUMENTATION for each item.)

1. For **HEMLIBRA (emicizumab)**, one of the following:
 Has a diagnosis of severe congenital hemophilia A
 Has a diagnosis of congenital hemophilia A with inhibitors
 Has a diagnosis of congenital hemophilia A and a history of at least one spontaneous episode of bleeding into a joint or other serious bleeding event

2. For a **BYPASSING AGENT** (e.g., FEIBA NF, NovoSeven):
For routine prophylaxis:
 Has hemophilia A with inhibitors AND (check all that apply):
 Failed to achieve clinical goals with Hemlibra
 Has a medical reason why Hemlibra cannot be used
 Has been using the requested bypassing agent for routine prophylaxis within the past 90 days
 Has hemophilia B with inhibitors
 Has acquired hemophilia
 Has congenital factor VII deficiency
 Has Glanzmann's thrombasthenia
For use other than routine prophylaxis (e.g., episodic/on-demand treatment, intermittent/periodic prophylaxis):
 Has hemophilia A with inhibitors

3. For a **non-preferred FACTOR VIII, FACTOR IX, or VWF**:
 Has been using the requested product within the past 90 days AND has a medical reason to continue using the requested product
 Failed to achieve clinical goals with or has a contraindication or an intolerance to the preferred FVIII, FIX, or FVIII/VWF products with the same half-life (standard v. extended half-life), if applicable. Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.
 Has a diagnosis for which no preferred Antihemophilia Agents are appropriate. Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.

RENEWAL REQUESTS

4. Experienced a positive clinical response since starting the requested medication: <input type="checkbox"/> Yes <input type="checkbox"/> No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

Coverage by Vista Health Plan, an independent licensee of the Blue Cross and Blue Shield Association.

CHCKF_233159912-10